Last reviewed · How we verify
fIPV at 6-14-22 weeks of age, Rotarix
fIPV (fractional-dose inactivated poliovirus vaccine) and Rotarix (rotavirus vaccine) stimulate the immune system to produce antibodies against poliovirus and rotavirus, respectively, preventing infection and disease.
fIPV (fractional-dose inactivated poliovirus vaccine) and Rotarix (rotavirus vaccine) stimulate the immune system to produce antibodies against poliovirus and rotavirus, respectively, preventing infection and disease. Used for Prevention of poliomyelitis (fIPV component), Prevention of rotavirus gastroenteritis (Rotarix component).
At a glance
| Generic name | fIPV at 6-14-22 weeks of age, Rotarix |
|---|---|
| Sponsor | Centers for Disease Control and Prevention |
| Drug class | vaccine |
| Modality | Biologic |
| Therapeutic area | Immunology |
| Phase | FDA-approved |
Mechanism of action
fIPV is an inactivated polio vaccine administered at reduced (fractional) doses to improve immunization coverage in resource-limited settings while maintaining protective immunity. Rotarix is a live attenuated rotavirus vaccine that replicates in the intestinal tract, inducing mucosal and systemic immune responses. Both vaccines work by priming B and T cells to recognize and neutralize their respective pathogens upon natural exposure.
Approved indications
- Prevention of poliomyelitis (fIPV component)
- Prevention of rotavirus gastroenteritis (Rotarix component)
Common side effects
- Fever
- Irritability
- Loss of appetite
- Diarrhea
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: